Crohn’s Disease
Takeda’s Alofisel fails to meet primary endpoint in phase 3 trial for Crohn’s disease complication
Takeda, following its decision to remove an early-stage Crohn’s disease candidate from its pipeline earlier this year, is now contending ...
AbbVie’s Skyrizi beats J&J’s Stelara in head-to-head Crohn’s disease trial
AbbVie’s Skyrizi has notched a resounding victory over Johnson & Johnson’s biologic drug Stelara in treating Crohn’s disease, as revealed ...
Lilly’s mirikizumab shows promise in Crohn’s disease after failing in psoriasis
After a previous setback when the FDA withheld approval for mirikizumab in ulcerative colitis due to manufacturing issues, Eli Lilly’s ...
Agomab raises $100M to advance its Crohn’s disease drug candidate
Agomab Therapeutics, in a remarkable stride forward, has secured an impressive $100 million in series C financing, just one week ...
AbbVie’s Skyrizi beats J&J’s Stelara in Crohn’s disease showdown
AbbVie’s revolutionary anti-inflammatory medication, Skyrizi, has been consistently outperforming its competitors in recent clinical trials, making waves in the field ...
Sandoz Enters US Immunology Market with Launch of High-Concentration Formulation Hyrimoz
Source – Novartis On July 1, 2023, Sandoz made an announcement regarding the availability of their biosimilar Hyrimoz (adalimumab-adaz) injection ...
